Preprint · CC-BY
via OpenAlex
Partial Epigenetic Reprogramming as a Strategy for Biological Aging Reversal: Preclinical Evidence, Mechanistic Framework, and the Transition to First-in-Human Clinical Trials
Zenodo (CERN European Organization for Nuclear Research) · 2026
Epigenetic alterations
Gene therapy
Partial reprogramming (OSK)
Non-human primate
Human
Mouse
Preclinical / animal
Review
Abstract
Biological aging has long been regarded as an immutable hallmark of living systems. However, recent breakthroughs in epigenetic science are fundamentally challenging this assumption. This review examines the theoretical foundations and experimental evidence supporting partial epigenetic reprogramming as a viable strategy to reverse cellular aging phenotypes while preserving cell identity. Central to this emerging framework is David Sinclair’s Information Theory of Aging, which proposes that the gradual degradation of epigenetic information—rather than the mere accumulation of genomic mutations—is the primary driver of organismal aging. Preclinical studies employing subsets of Shinya Yamanaka factors (OCT4, SOX2, KLF4; collectively referred to as OSK) have demonstrated remarkable outcomes, including: Restoration of youthful gene expression profiles, Reversal of epigenetic clock(definition) measurements by up to 75% of accumulated biological age markers, and Functional rejuvenation such as vision recovery, enhanced wound healing, and restored metabolic parameters in both murine and non-human primate models. Building upon this foundational work, Life Biosciences received U.S. Food and Drug Administration Investigational New Drug (IND) clearance in January 2026 for ER-100, the first gene therapy based on partial epigenetic reprogramming to advance into human clinical trials. The Phase 1 study targets open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), with primary endpoints emphasizing safety and tolerability. This review situates these developments within the broader landscape of longevity research, addresses the methodological limitations and ethical implications inherent to reprogramming-based interventions, and outlines prospective trajectories for the evolving field of age reversal biotechnology.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.5281/zenodo.18792926
- Canonical
- link ↗
- Fetched
- 2026-10-09 MST
Cite this
APA
Revista, Z. (2026). Partial Epigenetic Reprogramming as a Strategy for Biological Aging Reversal: Preclinical Evidence, Mechanistic Framework, and the Transition to First-in-Human Clinical Trials. <em>Zenodo (CERN European Organization for Nuclear Research)</em>. https://doi.org/10.5281/zenodo.18792926
Vancouver
Revista Z. Partial Epigenetic Reprogramming as a Strategy for Biological Aging Reversal: Preclinical Evidence, Mechanistic Framework, and the Transition to First-in-Human Clinical Trials. Zenodo (CERN European Organization for Nuclear Research). 2026. doi:10.5281/zenodo.18792926.
BibTeX
@unpublished{zen2026Partia,
title = {Partial Epigenetic Reprogramming as a Strategy for Biological Aging Reversal: Preclinical Evidence, Mechanistic Framework, and the Transition to First-in-Human Clinical Trials},
author = {Zen Revista},
journal = {Zenodo (CERN European Organization for Nuclear Research)},
year = {2026},
doi = {10.5281/zenodo.18792926},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Zenodo (CERN European Organization for Nuclear Research) 2026
Preprint · CC-BY
The Ontological Inversion of Biological Aging: Reconciling the Information Theory of Aging with the Nexus Constraint Framework
2026
Preprint
Molecular and Cellular Mechanisms of Aging: An Integrative Update on the Hallmarks, Emerging Regulators, and Translational Frontiers
European journal of immunology 2026
Citation only
Broken Engines of Immunity: Mitochondrial Dysfunction in T Cells Across Cancer and Complex Pathologies.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2026
Citation only
Epigenetic Information Loss and Chronosenescence in Liver Aging: From Molecular Mechanisms to Therapeutic Interventions.
Aging and Disease 2023
Open access · CC-BY
Hallmarks of Skin Aging: Update
Nature Communications 2020
Open access · CC-BY